CereVasc has announced treatment of the first patient in its clinical study of the eShunt system in patients with normal-pressure hydrocephalus (NPH).
Following approval from Argentina’s National Administration of Drugs, Foods and Medical Devices (ANMAT) to conduct the second study of the eShunt system in Argentina, the trial has been initiated under the leadership of Pedro Lylyk (Clínica La Sagrada Familia, Buenos Aires, Argentina) and is titled “Pilot study to evaluate the safety and effectiveness of the CereVasc eShunt system in the treatment of normal-pressure hydrocephalus”.
“Our experience with the eShunt system in patients with hydrocephalus secondary to post-aneurysmal subarachnoid haemorrhage has been promising with encouraging initial results,” said Lylyk. “The Clinica Sagrada Familia team is thrilled to expand the study of this minimally invasive, innovative device in patients with NPH, a condition that impacts many elderly patients. We believe the eShunt system could provide an attractive option to currently available treatments.”
